Insulin Sensitivity, Appetite, and Peptides Explained

Insulin resistance and appetite dysregulation are not separate problems — they're interconnected drivers of obesity that reinforce each other. Understanding how GLP-1 agonists and GH secretagogues interact with these systems explains why some peptides are dramatically more effective than others for fat loss, and why the right compound for each situation depends on the metabolic context.

How Insulin Resistance Drives Weight Gain and Hunger

Insulin resistance creates a self-reinforcing metabolic cycle:

Insulin resistance develops (chronic high-carb diet, excess body fat, inactivity)

Pancreas secretes more insulin to compensate → chronically elevated insulin

High insulin drives fat storage in adipose tissue and prevents lipolysis

Higher fat mass → more inflammation → worsening insulin resistance

Higher insulin also suppresses GH release from pituitary → reduced lean mass

Elevated ghrelin in high-insulin states drives hunger → more caloric intake

How GLP-1 Agonists Break This Cycle

GLP-1 agonists interrupt multiple points of the insulin resistance-obesity cycle simultaneously:

Reduce caloric intake → reduce fat mass → reduce systemic inflammation

Improve glucose-dependent insulin secretion → better blood sugar control without hypoglycaemia

Suppress inappropriate glucagon → reduce hepatic glucose output

Specifically reduce visceral (abdominal) fat, which is the metabolically active fat most strongly associated with insulin resistance

Reward pathway modulation reduces cravings for high-glycaemic food that perpetuates the cycle

Appetite Hormones and Peptide Interactions

Ghrelin

The 'hunger hormone' — secreted by the stomach when empty. Rises before meals, falls after eating. Chronically elevated in caloric restriction (the body fights back against dieting).

Peptide interaction:

Ipamorelin and GHRPs activate the ghrelin receptor but in a GH-focused manner. This may increase appetite slightly — a documented side effect of GHRPs, though milder with Ipamorelin than GHRP-6.

Leptin

The 'satiety hormone' — secreted by fat cells in proportion to fat mass. Signals the brain to reduce food intake when fat stores are adequate. Obese individuals often have elevated leptin but leptin resistance — the signal doesn't register.

Peptide interaction:

GH secretagogues may improve leptin sensitivity indirectly through improved body composition and reduced visceral fat. No direct peptide-leptin interaction documented at therapeutic doses.

PYY (Peptide YY)

Released from the gut after eating, particularly after protein and fat. Suppresses appetite by acting on the hypothalamus. High-protein meals produce robust PYY release — one mechanism by which protein is more satiating.

Peptide interaction:

GLP-1 and PYY are released from the same L-cells in the intestine simultaneously. GLP-1 agonists may upregulate PYY release, adding an additional satiety signal on top of the GLP-1 effect.

GIP (Glucose-Dependent Insulinotropic Polypeptide)

An incretin hormone released after meals. Stimulates insulin secretion. GIP receptors are also found in fat cells and brain.

Peptide interaction:

Tirzepatide directly agonises GIP receptors, adding this pathway to its GLP-1 effect — the basis of tirzepatide's dual-agonist mechanism and greater efficacy.

GH Secretagogues and Insulin Sensitivity: Both Sides

GH acutely reduces insulin sensitivity

Growth hormone directly antagonises insulin signalling in muscle and fat cells in the short term. This is the mechanism behind GH's diabetogenic effect at supraphysiological levels — e.g., exogenous HGH abuse.

But GH improves body composition, which improves insulin sensitivity long-term

Reduced visceral fat (GH is specifically lipolytic for visceral fat), increased lean mass (muscle is insulin-sensitive tissue), and reduced systemic inflammation all contribute to improved insulin sensitivity over a longer cycle.

GH secretagogues at physiological doses appear neutral to mildly positive

Research community data and limited studies suggest that GH secretagogues at standard doses (not supraphysiological HGH) produce modest if any insulin sensitivity changes. The body composition improvements may offset the direct GH-insulin antagonism.

Diabetics and insulin-resistant individuals need caution

Anyone with pre-existing insulin resistance, metabolic syndrome, or type 2 diabetes who uses GH secretagogues should monitor glucose carefully. The acute GH-induced insulin resistance is a real pharmacological effect that requires management.

Educational context only. This article describes mechanisms for research understanding. Not medical advice for any condition.

Weight Loss Peptides Guides

→ Semaglutide Dosage Guide → Tirzepatide vs Semaglutide → Why Semaglutide Doesn't Work for Some → How GLP-1 Agonists Work → Tesofensine Results → Best Peptides for Fat Loss (Ranked)